Statins and immune checkpoint inhibitors: a strategy to improve the efficacy of immunotherapy for cancer?

Research output: Contribution to journalArticleAcademicpeer-review


In the past decade, immune checkpoint inhibitor (ICI) therapy significantly improved the prognosis of patients with cancer. Despite impressive and often unprecedented response rates, a significant portion of the patients fails to benefit from this treatment. Additional strategies to improve ICI efficacy are therefore needed. The widespread clinical use of ICIs has increased our knowledge on the effects of the concomitant use of commonly prescribed drugs on the outcome of ICI treatment. A particular interesting class of drugs in this context are statins. These HMG-CoA reductase inhibitors, which are used to treat hypercholesterolemia and reduce the risk for atherosclerotic cardiovascular disease, are frequently used by patients with (advanced) cancer. This paper addresses the hypothesis that statins improve the efficacy of ICI therapy.
Original languageEnglish
Article numbere005611
JournalJournal for Immunotherapy of Cancer
Issue number9
Publication statusPublished - 2 Sept 2022


  • immunotherapy

Cite this